You are here: Industry Insights > RSV vaccine

News List

GSK launches late-stage study of RSV vaccine in pregnant mothers pharmatimes
November 25, 2020
GlaxoSmithKline (GSK) has kicked off a phase III study of its Respiratory Syncytial Virus (RSV) vaccine candidate for maternal immunisation.
Meissa begins pre-clinical studies of Covid-19 intranasal vaccine pharmaceutical-technology
July 02, 2020
US-based biotechnology company Meissa Vaccines has started preclinical studies and manufacturing of its intranasal, live attenuated vaccine (LAV) candidate MV-014-210 against Covid-19.
Eyeing a $6B market, Bavarian Nordic posts positive phase 2 data for universal RSV vaccine fiercepharma
June 29, 2017
Chasing a big market opportunity that recently tripped up another vaccine developer, Bavarian Nordic reports that a single shot of its universal respiratory syncytial virus (RSV) candidate can elicit a significant immune response shortly after vaccination
St. Jude Children’s Research Hospital to commercialise RSV vaccine europeanpharmaceuticalreview
May 15, 2017
St. Jude Children’s Research Hospital and the Serum Institute of India have signed a licensing agreement to complete development and commercialisation of a St. Jude vaccine against the respiratory syncytial virus (RSV), the virus that causes croup and low
AZ and Sanofi link on RSV vaccine pharmatimes
March 06, 2017
AstraZeneca's MedImmune is partnering with Sanofi's vaccines arm Sanofi Pasteur on the development and...
Novavax still gunning for first-to-market status in RSV: CEO fiercepharma
March 01, 2017
Novavax isn’t letting a bruising phase 3 failure for its RSV vaccine kill its enthusiasm around the program. In fact, management still figures the biotech leads its much larger competitors in a lucrative field.